Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Santa Fe BioLabs General Information
Santa Fe BioLabs has developed proprietary culture media and assays—ReCand and AuriFind—for the optimized recovery, identification, and selective growth of viable Candida auris from environmental or clinical samples. These tools address shortcomings in conventional methods by improving sensitivity for dry-stressed cells. The company holds patents on these technologies. Their products are intended to help prevent outbreaks of this dangerous yeast in healthcare settings.
Contact Information
Primary Industry
Molecular Diagnostics
Corporate Office
Pantego, Texas
United States
United States
Drug Pipeline
ReCand
Pre-clinicalKey Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Santa Fe BioLabs Funding
No funding data available
To view Santa Fe BioLabs's complete valuation and funding history, request access »